Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.54 |
| ▸ | SI | P14410 | 1/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20011810 | 0.88 | GAA (0.45) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL17501817 | 0.81 | MGAM (0.42) | GAAMGAMSIMGAM2CA12 | |
| SCHEMBL29215034 | 0.81 | EGLN1 (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL20011966 | 0.78 | USP2 (0.40) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4414359 | 0.78 | GAA (0.56) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL9598083 | 0.76 | GAA (0.54) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL16485863 | 0.76 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL21272575 | 0.76 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL19216683 | 0.76 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL31644338 | 0.75 | APOBEC3A (0.47) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| CN-116854681-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-20190308973-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | ARDELYX, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308973-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | ARDELYX, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190233420-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3504205-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | Ardelyx, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2019034725-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-21 | — | — | WO | disclosed |
| WO-2018039386-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20170217899-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170217899-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2017-08-03 | — | — | US | disclosed |
| WO-2016020441-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308973-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | FXR1, FXR2, NR1H4 | GAA 3871/4885MGAM 4792/4885SI 437/4885 |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | GAA 3871/4885MGAM 4792/4885SI 437/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | GAA 290/4885MGAM 863/4885SI 1984/4885 |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GAA 94/4885MGAM 163/4885SI 2231/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | GAA 2258/4885MGAM 3777/4885SI 1424/4885 |
| US-20170217899-A1 | NOVEL HALOGEN-SUBSTITUTED COMPOUNDS | CYP4F3, SLC39A3, C1S | GAA 3168/4885MGAM 3899/4885SI 3546/4885 |
| US-20190233420-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | GAA 2231/4885MGAM 3855/4885SI 1306/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | GAA 94/4885MGAM 163/4885SI 2231/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | GAA 2258/4885MGAM 3777/4885SI 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.